Moderate-Intensity Aerobic Calisthenics for Rural Elderly With Motoric Cognitive Risk Syndrome
2026年6月14日 更新者：Yuanjiao Yan、Fujian Provincial Hospital
A Study on the Application of Moderate-Intensity Aerobic Calisthenics in Rural Elderly With Motoric Cognitive Risk Syndrome
The aging of China's rural population is severe, with both the prevalence and mortality rates of dementia higher in rural areas than in urban areas.
Motor Cognitive Risk Syndrome (MCR), as a novel pre-dementia syndrome characterized by both subjective cognitive decline and slow gait, represents a "golden window of opportunity" for the early prevention and treatment of dementia.
Currently, there is no specific pharmacological treatment for MCR; non-pharmacological interventions, particularly exercise interventions, are key strategies.
Moderate-intensity aerobic calisthenics, which integrates music, dance, and gymnastic elements, is economical, simple, highly engaging, safe, and has demonstrated potential for improving both cognitive and gait function, making it especially suitable for promotion in resource-limited rural settings.
However, there is a lack of systematic, theory-guided exercise intervention protocols and effectiveness validation for rural older adults with MCR.
Therefore, this study aims to develop and validate a moderate-intensity aerobic calisthenics intervention protocol tailored to this population.
調査の概要
詳細な説明
Motor Cognitive Risk Syndrome (MCR), first defined by Verghese et al. in 2013, refers to the coexistence of subjective cognitive decline and slow gait in older adults without dementia or movement disorders, representing a novel pre-dementia syndrome situated between normal aging and dementia. The global prevalence of MCR is 9.0% (range: 2.4%-33.3%) , and the prevalence among Chinese older adults ranges from 4.00% to 13.85% , with higher rates in rural than urban areas-reaching as high as 16.7% in rural Anhui Province. MCR significantly increases the risk of dementia (three-fold) and particularly vascular dementia (12-fold) , and also elevates the incidence of falls, disability, and mortality. Cohort studies have shown that 22.1% of individuals with MCR progress to dementia, 57.5% remain in the MCR state, and 20.3% revert to normal cognition. This reversibility suggests that MCR represents a critical window for the ultra-early prevention and treatment of dementia.
Moderate-intensity aerobic calisthenics, which integrates music, dance, and gymnastic elements, is a form of moderate-intensity aerobic exercise. Evidence indicates that it effectively improves cognitive and physical function in older adults, exerts superior cognitive benefits compared to other exercise types, and reduces loneliness and depressive symptoms. The participation rate in physical exercise among older adults in rural China is only 33.9%-48.29%, limited by objective constraints such as lack of facilities and equipment, and monotonous forms of exercise. Aerobic calisthenics, characterized by its economy, simplicity, high appeal, and safety, is well-suited for promotion in rural areas. However, no studies to date have reported the application effects of this intervention in the MCR population, and thus investigating its intervention value in rural older adults with MCR holds significant research importance.
研究の種類
介入
入学 (推定)
106
段階
- 適用できない
連絡先と場所
このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。
研究連絡先
- 名前：Tuantuan Guo
- 電話番号：+86 159 5989 7344
- メール：390977233@qq.com
研究場所
-
-
Fujian
-
Fuzhou、Fujian、中国、350100
- Fujian Medical University
-
-
参加基準
研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
はい
説明
Inclusion Criteria:
Age ≥60 years;
Meeting the diagnostic criteria for Motor Cognitive Risk Syndrome (MCR);
Clear consciousness and ability to communicate clearly;
- Permanent residents of rural areas in nine prefecture-level cities of Fujian Province (with an annual residence of ≥9 months) and no plan to relocate within the next year; -⑤ Willing to voluntarily participate and sign the informed consent form.
Exclusion Criteria:
Presence of severe mental disorders, history of stroke, Parkinson's disease, or severe visual/auditory impairments;
Physical disability that prevents independent walking;
- Comorbid severe systemic diseases, such as cardiopulmonary conditions; -④ Regular exercise habits within the past 6 months (≥30 minutes/day, ≥3 days/week) or a long-term history of exercise; -⑤ Current participation in other interventional studies.
研究計画
このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：支持療法
- 割り当て：ランダム化
- 介入モデル：並列代入
- マスキング：ダブル
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的：Moderate-intensity aerobic exercise
The group was intervened with a moderate-intensity aerobic exercise program developed by the research team.
|
Based on routine health education, the intervention group receives a 12-week moderate-intensity aerobic exercise intervention (Jiamusi Happy Dance Steps) lasting 60 minutes per session, three times per week, delivered in a group setting, followed by a 12-week follow-up period.
|
|
実験的：Routine Care
This group of elderly people maintained their daily routines and received health education.
|
While maintaining daily living habits unchanged, provide knowledge related to health education for Motor Cognitive Risk Syndrome (MCR) and receive the MCR health education manual.
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Montreal Cognitive Assessment Basic
時間枠：The intervention was carried out in August 2026, and the assessment period was 0,3,6 months.
|
The MoCA-B was jointly developed by the Montreal Cognitive Assessment Clinic and Research Institute in Canada, in collaboration with the Prince Mahidol Award Foundation of Thailand and the Faculty of Medicine at Chulalongkorn University.
It has a total score of 30 points and encompasses eight cognitive domains: executive function, language, orientation, calculation, abstract thinking, memory, visual perception, and attention, with higher scores indicating better cognitive function.
The cutoff values are as follows: for years of education ≤6 years, MoCA-B ≥20; for 6 years < years of education ≤12 years, MoCA-B ≥23; and for years of education >12 years, MoCA-B ≥25.
The scale correctly identifies cognitively normal participants with a specificity of 86%, and demonstrates a sensitivity of 81% for detecting cognitive impairment.
The Cronbach's α coefficient of the scale is 0.807, and the criterion valid
|
The intervention was carried out in August 2026, and the assessment period was 0,3,6 months.
|
|
Walking speed
時間枠：The intervention was carried out in August 2026, and the assessment period was 0,3,6 months.
|
The timed walking test was used to measure gait speed.
The required equipment included a tape measure and a stopwatch.
The specific procedure was as follows: First, a straight 6-meter course was measured using the tape measure, and the middle 4-meter segment was marked.
The participant stood at the starting point.
Then, upon the tester's command "Start," the participant walked at their normal pace to the endpoint.
The time taken to cover the middle 4 meters was recorded using the same stopwatch.
This was performed twice.
Finally, gait speed was calculated using the formula speed = distance / time, with the average time of the two trials used for calculation.
|
The intervention was carried out in August 2026, and the assessment period was 0,3,6 months.
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Subjective Cognitive Decline-questionnaire 9
時間枠：The intervention was carried out in August 2026, and the assessment period was 0,3,6 months.
|
The SCD-Q9 was adapted and revised into Chinese by Hao Lixiao et al.
It encompasses two dimensions: global memory ability with time comparison, and activities of daily living.
It primarily assesses memory, recall ability, language ability, attention, orientation, and other domains.
The questionnaire consists of 9 items.
The scoring reference criteria for item responses are as follows: "Yes" = 1 point, "No" = 0 points, "Often" = 1 point, "Occasionally" = 0.5 points.
The total score ranges from 0 to 9 points, with higher scores indicating a greater likelihood of cognitive impairment.
A score of ≥5 points suggests the possible presence of potential memory impairment.
|
The intervention was carried out in August 2026, and the assessment period was 0,3,6 months.
|
|
short physical performance battery
時間枠：The intervention was carried out in August 2026, and the assessment period was 0,3,6 months.
|
The Short Physical Performance Battery (SPPB), developed by the National Institute on Aging (NIH), objectively assesses balance, lower limb strength, and physical function in older adults.
Originally designed to predict disability, institutionalization, or mortality, it is now widely used for frailty, fall risk, and disease-related functional impairment.
The SPPB includes three tests: balance, 4-meter gait speed, and five-repetition sit-to-stand, each scored 0-4, total 0-12 (higher = better function).
Scores 0-3: severe mobility limitation with daily living difficulties; 4-6: mild limitation, needing assistance or aids; 7-9: normal mobility, independent in daily activities; 10-12: excellent mobility, robust and strong.
|
The intervention was carried out in August 2026, and the assessment period was 0,3,6 months.
|
|
Handgrip strength
時間枠：The intervention was carried out in August 2026, and the assessment period was 0,3,6 months.
|
A electronic hand dynamometer (CAMRY, USA) was used to assess the upper limb muscle strength of the participants.
Before measurement, the staff adjusted the dynamometer to zero.
During the test, the participant stood in a natural posture with both arms hanging naturally at the sides.
The dynamometer was kept as suspended as possible without touching the body, while maintaining the device stable.
The participant was instructed to relax and then squeeze the dynamometer forcefully with the dominant hand three times (with an interval of >15 seconds between each attempt).
The maximum value among the three attempts was recorded as the grip strength.
|
The intervention was carried out in August 2026, and the assessment period was 0,3,6 months.
|
|
Body fat
時間枠：The intervention was carried out in August 2026, and the assessment period was 0,3,6 months.
|
Body composition was assessed using bioelectrical impedance analysis (BIA) with an InBody H20N body fat scale, primarily measuring muscle and fat-related parameters.
Before testing, participants wore light clothing without metal accessories and removed metal items such as watches, rings, and necklaces.
During testing, participants stood barefoot on the metal electrode plates with feet shoulder-width apart, ensuring close contact of heels and forefeet with the plates.
They held the handles on both sides with arms hanging naturally, hands dry and not touching the trunk.
The operator initiated the measurement, during which participants remained still, silent, and motionless.
The measurement lasted 1-2 minutes, and the device introduced a low-intensity electrical current to determine bioelectrical impedance parameters and estimate body composition.
|
The intervention was carried out in August 2026, and the assessment period was 0,3,6 months.
|
|
12-Item Short-Form Health Survey
時間枠：The intervention was carried out in August 2026, and the assessment period was 0,3,6 months.
|
The SF-12, a shortened version of the 36-Item Short-Form Health Survey (SF-36), assesses health-related quality of life.
It retains the eight dimensions of the SF-36 with 12 items, covering general health (GH), physical functioning (PF), role physical (RP), bodily pain (BP), role emotional (RE), mental health (MH), vitality (VT), and social functioning (SF).
The first four dimensions evaluate physical component summary (PCS), and the latter four evaluate mental component summary (MCS).
The total score ranges from 0 to 100, with higher scores indicating better quality of life.
Xiao Huimin et al. demonstrated good reliability and validity of the SF-12 among Chinese older adults.
|
The intervention was carried out in August 2026, and the assessment period was 0,3,6 months.
|
|
Patient Health Questionnaire-9
時間枠：The intervention was carried out in August 2026, and the assessment period was 0,3,6 months.
|
The 9-item Patient Health Questionnaire (PHQ-9) assesses depressive symptom severity over the past two weeks.
Each item is rated on a 4-point scale (0 = not at all, 1 = several days, 2 = more than half the days, 3 = nearly every day), with a total score ranging from 0 to 27 (higher scores indicate greater depression severity).
Cutoff scores: 0-4 = no depression; 5-9 = possible mild depression; 10-14 = moderate depression risk; ≥15 = severe depressive symptoms.
The scale has good internal consistency (Cronbach's α = 0.894).
|
The intervention was carried out in August 2026, and the assessment period was 0,3,6 months.
|
|
Generalized Anxiety Disorder-7 item
時間枠：The intervention was carried out in August 2026, and the assessment period was 0,3,6 months.
|
The 7-item Generalized Anxiety Disorder scale (GAD-7) assesses the severity of anxiety symptoms over the past two weeks.
Each item is rated on a 4-point scale (0 = not at all, 1 = several days, 2 = more than half the days, 3 = nearly every day), with a total score ranging from 0 to 21 (higher scores indicate greater anxiety severity).
Cutoff scores: 0-4 = no anxiety; 5-9 = mild anxiety; 10-14 = moderate anxiety; ≥15 = severe anxiety.
The scale has good internal consistency (Cronbach's α = 0.840) and demonstrates good reliability and validity in the Chinese population.
|
The intervention was carried out in August 2026, and the assessment period was 0,3,6 months.
|
|
World Health Organization Well-being Index
時間枠：The intervention was carried out in August 2026, and the assessment period was 0,3,6 months.
|
The WHO-5 Well-Being Index, developed by Bech and revised by the WHO Collaborating Centre for Research in Mental Health, assesses subjective well-being over the past two weeks.
The scale consists of 5 items, each rated on a 6-point scale (0 = none, 1 = a little of the time, 2 = less than half the time, 3 = more than half the time, 4 = most of the time, 5 = all the time).
The raw sum is multiplied by 4 to obtain a standardized total score ranging from 0 to 100, with higher scores indicating better well-being.
The scale has good internal consistency (Cronbach's α = 0.86) .
A score below 50 indicates reduced well-being [144].
In this study, well-being is categorized as high (≥70), moderate (50-70), and low (≤50).
|
The intervention was carried out in August 2026, and the assessment period was 0,3,6 months.
|
|
The Theory of Planned Behavior Questionnaire (Exercise Version)
時間枠：The intervention was carried out in August 2026, and the assessment period was 0,3,6 months.
|
The Theory of Planned Behavior Questionnaire, developed by Icek Ajzen, consists of 12 items across four dimensions: behavioral attitude, subjective norm, perceived behavioral control, and behavioral intention.
It is used to measure the social cognitive variables of the theory of planned behavior.
The target behavior in this questionnaire refers to the exercise goal set for rural older adults with Motor Cognitive Risk Syndrome (i.e., participating in at least 150 minutes of moderate-intensity aerobic exercise per week).
Items are rated on a 7-point Likert scale, ranging from "strongly disagree" to "strongly agree," with scores from 1 to 7. Higher scores indicate greater levels of agreement.
|
The intervention was carried out in August 2026, and the assessment period was 0,3,6 months.
|
協力者と研究者
ここでは、この調査に関係する人々や組織を見つけることができます。
研究記録日
これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。
主要日程の研究
研究開始 (推定)
2026年7月1日
一次修了 (推定)
2026年7月31日
研究の完了 (推定)
2027年1月31日
試験登録日
最初に提出
2026年6月14日
QC基準を満たした最初の提出物
2026年6月14日
最初の投稿 (実際)
2026年6月22日
学習記録の更新
投稿された最後の更新 (実際)
2026年6月22日
QC基準を満たした最後の更新が送信されました
2026年6月14日
最終確認日
2026年6月1日
詳しくは
本研究に関する用語
その他の研究ID番号
- 2026-04-27
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
はい
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
いいえ
米国FDA規制機器製品の研究
いいえ
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。